Published in Virchows Arch on August 03, 2007
Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A (2008) 2.87
The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis (2009) 1.50
Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J Biol Chem (2011) 1.29
The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther (2009) 1.18
Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci (2012) 1.00
Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther (2012) 0.99
Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis (2013) 0.95
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics (2008) 0.93
Renal complications of Fabry disease in children. Pediatr Nephrol (2012) 0.93
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase. PLoS One (2015) 0.93
Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. PLoS One (2012) 0.91
Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One (2013) 0.88
Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol (2008) 0.87
Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol (Lausanne) (2014) 0.87
Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice. Acta Neuropathol Commun (2014) 0.85
Carpal tunnel syndrome in fabry disease. JIMD Rep (2011) 0.83
Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet (2016) 0.82
Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice. Mol Ther (2015) 0.82
Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections. Virchows Arch (2011) 0.82
Increased urinary CD80 excretion and podocyturia in Fabry disease. J Transl Med (2016) 0.80
Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease. Mol Genet Metab (2013) 0.80
A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts. JIMD Rep (2015) 0.79
Vascular tortuosities of the upper eyelid: a new clinical finding in fabry patient screening. J Ophthalmol (2013) 0.79
Leukocyte perturbation associated with Fabry disease. J Inherit Metab Dis (2009) 0.78
Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene. BMC Genet (2015) 0.77
Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide. PLoS One (2015) 0.77
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2008) 0.75
Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Therap Adv Gastroenterol (2016) 0.75
Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. Int J Nephrol (2017) 0.75
Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease. PLoS One (2016) 0.75
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev (1998) 8.74
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature (2005) 7.72
Bi-directional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol (2004) 6.10
Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med (1967) 5.63
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch (2005) 2.45
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant (2005) 1.84
GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell (2004) 1.64
Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke (2001) 1.56
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve (2003) 1.51
Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 1.46
Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation (2005) 1.28
Clinical features of and recent advances in therapy for Fabry disease. JAMA (2000) 1.21
Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis (2005) 1.20
Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem (2003) 1.18
Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol (1988) 1.16
Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. Philos Trans R Soc Lond B Biol Sci (2003) 1.16
Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients. Clin Experiment Ophthalmol (2006) 1.13
Effect of tissue processing on colloidal gold cytochemistry. J Histochem Cytochem (1987) 1.09
Antigen unmasking for immunoelectron microscopy: labeling is improved by treating with sodium ethoxide or sodium metaperiodate, then heating on retrieval medium. J Histochem Cytochem (1995) 1.07
Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J Biol Chem (2003) 1.05
The human CD77- B cell population represents a heterogeneous subset of cells comprising centroblasts, centrocytes, and plasmablasts, prompting phenotypical revision. J Immunol (2006) 1.02
Gangliosides as apoptotic signals in ER stress response. Cell Death Differ (2006) 1.01
Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine. Arch Biochem Biophys (1994) 0.97
Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. J Biol Chem (2003) 0.97
Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res (2002) 0.95
Sustained elevation of calcium induces Ca(2+)/calmodulin-dependent protein kinase II clusters in hippocampal neurons. Neuroscience (2001) 0.95
Intracellular trafficking of sphingolipids: relationship to biosynthesis. Biochim Biophys Acta (2006) 0.94
Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivity. Neuroscience (1995) 0.93
Tissue distribution of glycosphingolipids in a case of Fabry's disease. J Lipid Res (1969) 0.93
Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol (1990) 0.92
CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J Cell Physiol (1998) 0.90
A female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody. Am J Kidney Dis (1995) 0.89
Verotoxin/globotriaosyl ceramide recognition: angiopathy, angiogenesis and antineoplasia. Biosci Rep (1999) 0.89
Genetic diseases of sphingolipid metabolism: pathological mechanisms and therapeutic options. FEBS Lett (2006) 0.89
Sphingomyelinase causes endothelium-dependent vasorelaxation through endothelial nitric oxide production without cytosolic Ca(2+) elevation. FEBS Lett (2005) 0.88
Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci U S A (2007) 0.87
Establishment of a monoclonal antibody directed against Gb3Cer/CD77: a useful immunochemical reagent for a differentiation marker in Burkitt's lymphoma and germinal centre B cells. Glycoconj J (1997) 0.86
Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. Neuropathol Appl Neurobiol (2005) 0.85
Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits. Virchows Arch (2000) 0.82
Monoclonal antibodies against Gal alpha 1-4Gal beta 1-4Glc (Pk, CD77) produced with a synthetic glycoconjugate as immunogen: reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. Int J Cancer (1991) 0.78
Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with Fabry disease. Br J Dermatol (2005) 0.78
Localization of DNA adducts induced by N-acetoxy-N-2-acetylaminofluorene in Chinese hamster ovary cells using electron microscopy and colloidal gold. Genes Chromosomes Cancer (1990) 0.77
Immunofluorescence analysis of trihexosylceramide accumulated in the hearts of variant hemizygotes and heterozygotes with Fabry disease. Am J Cardiol (1996) 0.75
Chemical structure of the main glycolipid of hog erythrocytes. Jpn J Exp Med (1968) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med (2014) 4.00
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet (2007) 3.43
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet (2006) 2.83
Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet (2007) 2.81
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network. Nat Cell Biol (2004) 2.59
Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol (2006) 2.59
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab (2004) 2.46
Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch (2005) 2.45
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet (2013) 2.42
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol (2012) 2.33
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood (2012) 2.22
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. J Neurosci (2006) 1.87
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus. Nat Genet (2012) 1.82
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr (2003) 1.75
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve (2002) 1.70
T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature (2008) 1.68
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog (2006) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy. Am J Hum Genet (2011) 1.67
A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog (2006) 1.66
Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology (2005) 1.66
Role of ABO secretor status in mucosal innate immunity and H. pylori infection. PLoS Pathog (2008) 1.64
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology (2005) 1.63
Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology (2006) 1.62
Ethyl pyruvate decreased early nuclear factor-kappaB levels but worsened survival in lipopolysaccharide-challenged mice. Crit Care Med (2008) 1.62
Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation (2006) 1.61
Rab10 is involved in basolateral transport in polarized Madin-Darby canine kidney cells. Traffic (2006) 1.61
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61
Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus. Ann Neurol (2002) 1.60
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3). Mol Genet Metab (2009) 1.56
Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study. BMC Neurol (2008) 1.51
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
Absence of simian virus 40 in human brain tumors from northern India. Int J Cancer (2002) 1.50
Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology (2006) 1.44
Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol (2003) 1.44
Pediatric Fabry disease. Pediatrics (2005) 1.43
New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol (2002) 1.42
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J (2010) 1.42
Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet (2003) 1.41
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation (2005) 1.40
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol (2009) 1.40
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity? J Clin Endocrinol Metab (2004) 1.38
Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. Am J Hum Genet (2011) 1.38
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol (2011) 1.31
Characterization of tiger-tail banding and hair shaft abnormalities in trichothiodystrophy. J Am Acad Dermatol (2005) 1.30
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res (2006) 1.26
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Downregulation of myelination, energy, and translational genes in Menkes disease brain. Mol Genet Metab (2005) 1.24
White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull (2003) 1.23
Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurooncol (2007) 1.23
Characterization of two molluscan crystal-modulating biomineralization proteins and identification of putative mineral binding domains. Biopolymers (2003) 1.23
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol (2006) 1.23
Hepatic abscess in patients with chronic granulomatous disease. Ann Surg (2002) 1.22
Transfer of a mitochondrial DNA fragment to MCOLN1 causes an inherited case of mucolipidosis IV. Hum Mutat (2004) 1.22
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2013) 1.21